# The webinar will begin in:









WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION

## Questions/concerns


# patentscope@wipo.int





# Free-of-charge

- No cost
- Available to all: <a href="https://patentscope.wipo.int">https://patentscope.wipo.int</a>



Using PATENTSCOPE you can search 104 million patent documents including 4.3 million published international patent applications (PCT). Detailed coverage information

PCT publication 22/2022 [02.06.2022] is now available here. The next PCT publication 23/2022 is scheduled for 09.06.2022. More

Check out the new PATENTSCOPE features: CPC, NPL, Families ...

Search Facility to Support COVID-19 Innovation Efforts

Field


Front Page

Search terms...

Q

Query Examples


## Account



Query Examples

## Benefits of account: RSDAW


- RSS
- **S**ave
- Download
- Access
- Wildcards & Watched applications




## **SAVED QUERIES**

These are all queries saved in your PATENTSCOPE profile. They are available every time you log in!

Name	Search for	Offices	Sort by	Stem	Single Family Member	Page	Size	Private	
Electric car	FP:(EN_TI:"electric car")	All	Relevance			1	10		Î A Q
Wind turbine	EN_AB:"wind turbine"	All	Relevance			1	10	<b>V</b>	Î A Q
Magnetic chip	EN_AB:"magnetic chip"	All	Relevance			1	10	<b>V</b>	Ū 37 Q
test		All	Relevance			1	10	<b>V</b>	DâQ
human space flight	EN_ALL:"human space flight" OR "manned space flight" OR "crewed space flight" OR "human spaceflight" OR "manned spaceflight" OR "crewed spaceflight" OR FP:(((EN_TI:("space flight human"~21 OR "space flight human"~21 OR "space aircraft human"~21 OR "space airborne human"~21 OR "space aircrew human"~21 OR "spatial flight human"~21 OR "spatial flying human"~21 OR "spatial aerial human"~21 OR "spatial aircraft human"~21 OR "spatial airborne human"~21 OR "spatial aircrew human"~21 OR "shuttle flight human"~21 OR "space aerial human"~21 OR "space flight human"~21 OR "space aerial human"~21 OR "space aircraft human"~21 OR "space aircrew human"~21 OR "space aircrew human"~21 OR "spatial aircrew human"~21 OR "space flight human"~21 OR "space aircraft human"~21 OR "space aircraft human"~21 OR "space aircrew human"~21 OR "space aircrew human"~21 OR "space aircraft human"~21 OR "space aircrew human"~21 OR "spatial flight human"~21 OR "spatial aircrew human"~21 OR "spatial aircraft human"~21 OR	All	Relevance			1	10		<u>0</u> 2





### CHEMICAL COMPOUNDS SEARCH -

Convert structure	Upload structure		Structure editor	Found compounds	Found Markush Formulas			
Search type Compound name		~	Type an accepted name, cor	nmercial name, CAS nar	nme, IUPAC name			
☐ Search for scaf	fold							
☐ Include enume	rated Markush structu	res						
Offices All								•
						Reset	Show in editor	Exact Structure Search

487,911 results Offices all Languages all Stemming true Single Family Member false Include NPL false

Sort: Relevance ▼ Per page: 100 ▼ View: All+Image ▼


1/4,880 ▼ >



#### 1. 106143720 BALANCE CAR

Int.Class B62K 3/00 ? Appl.No 102016000525593 Applicant SHANG YANYAN Inventor SHANG YANYAN


The invention discloses a balance car. The balance car comprises a balance car body and a car rod arranged on the balance car body. The car rod operating part and a car rod steering part. The car rod steering part is connected with the balance car body. The length of the car rod operating part is smaller than that of the car rod steering part. The car rod operating part and the car rod steering part and t connected through rotary shafts. When the balance car is folded, the car rod operating part rotates to get close to and be attached to the car rod steering part. Due to the fact that the length of the car rod operating part is smaller than that of the car rod steering part, the control effect applied by the car rod on the balance car for use cannot be affected after the balance car is folded, the car rod of the balance car can still be normally used after being folded, a user can operate and control the car rod steering part through the legs, the height of the balance car is reduced after the car rod is folded, and the user can normally use the balance car in places with the limitation to the space height or on the occasions where the balance car can be used only by being temporarily folded slightly.



#### 2. 1020190024240 CAR HIRING SERVICE SYSTEM INCLUDING SECURITY FUNCTION

Int.Class G06Q 30/06 ② Appl.No 1020170111032 Applicant 동국대학교 산학협력단 Inventor KIM, W00NG SUP

The present invention relates to a car hiring service system including a security function. According to a car hiring service, which allows car hiring between a car lender and a user by lending a car registered by the car lender to a car user who needs a car through a car hiring server after cost payment, a car terminal for sensing whether a car drives, communicating with the car hiring server, and connected to a car user terminal through a short distance wireless communication using a beacon to perform user authentication, is provided in a rental car of the car lender. Therefore, when the authenticated car user uses the rental car of the car lender, the driving of a corresponding car is checked through the car terminal, and also, connection of the short distance wireless communication with the car user terminal is periodically sensed to transmit a warning message to the car lender and the authenticated car user terminal when the short distance communication is not connected with the car user terminal in a car driving state other than a car parking/stopping state, thereby effectively preventing car theft or loss, or illegal use of a car by a unauthorized user to improve the security, COPYRIGHT KIPO 2019



#### 2001006100 AUTOMATIC FOLLOWING TRAVELING SYSTEM

Int.Class G08G 1/16 ? Appl.No 1999177530 Applicant HONDA MOTOR CO LTD Inventor TAMURA KAZUYA

PROBLEM TO BE SOLVED: To reduce the calculating processing load of each vehicle and to reduce communication buffer capacity.

SOLUTION: A following car is provided with a preceding car position detecting means C for detecting the position information of a preceding car on a present car coordinate system, a preceding car coordinate system present car position correcting means D for correcting the present car position information from the present car coordinate system to a preceding car coordinate system on the basis of the position information of the preceding car on the present car coordinate system, present car position information on the present car coordinate system and preceding car position information I1 on the preceding car coordinate system transmitted by inter-car communication, a leading car coordinate system present car position correcting means E for correcting the present car position information corrected to the preceding car coordinate system to a leading car coordinate system and a vehicle control means F for traveling the present car while following the leading car on the basis of the result corrected by the leading car coordinate JP - 12.01.2001

HERFOR  $(\Delta x, \Delta y, \Delta \theta)_{2-4}$   $(\Delta x, \Delta y, \Delta \theta)_{3-2}$   $(\Delta x, \Delta y, \Delta \theta)_{4-3}$ 

### 1. W02017107165 - MULTI-LEVEL OVEN



PCT Biblio. Data Full Text Drawings ISR/W0SA/A17[2][a] National Phase Notices Documents

						Permal
	International A	pplication Status				
Date	Title		View		Download	
20.09.2021	International Application Status Report		HTML. PDF. XML		PDF. XML	
	Published Interna	ational Application				
Date	Title	View		Download	ı	<u>Q</u>
29.06.2017	Initial Publication with ISR[ [A1 26/2017]]	<u>PDF (25p.</u>	PDF [25p.]		). <u>ZIP(XML + TIFFs).FullText</u>	
	Search and Examinat	ion-Related Documents				
Date	Title	View		Download	I	2
26.06.2018	[IB/373] International Preliminary Report on Patentability Chapter I	PDF (4p.)		PDF (4p.).	ZIP(XML + TIFFs)	
30.04.2018	English Translation of the Written Opinion of the International Searching Authority	<u>PDF [5p.]</u>		PDF (5p.).	ZIP(XML + TIFFs)	
29.06.2017	[ISA/210] International Search Report	<u>PDF (5p.)</u>		PDF (5p.).	ZIP(XML + TIFFs).FullText	
29.06.2017	Translation of the ISR	PDF [3p.]		PDF (3p.).	ZIP(XML + TIFFs)	
29.06.2017	[ISA/237] Written Opinion of the International Searching Authority	PDF (3p.)		PDF (3p.1.	ZIP(XML + TIFFs).FullText	


### **DOCUMENTS DOWNLOAD**

You currently have 5 documents, totaling 36 pages, selected for download.

Application \$	Date ≎	Title \$	Filename \$	Pages \$	Remove
W02021098647	27.05.2021	Translation of the ISR	W02021098647-ETISR-20210527-2841.pdf	3	Û
W02021098647	27.05.2021	[ISA/237] Written Opinion of the International Searching Authority	W02021098647-W0SA-20210527-0870.pdf	3	Û
W02017124775	24.07.2018	[IB/373] International Preliminary Report on Patentability Chapter I	W02017124775-IPRP1-20180724-9715.pdf	5	Û
W02017124775	27.07.2017	[ISA/210] International Search Report	W02017124775-ISR-20170727-6934.pdf	4	Û
W02011120124	06.10.2011	Initial Publication with ISR	W02011120124-PAMPH-20111006-2279.pdf	21	Û

Reset


Download



## Where to find what?

- Help menu
- Search menu
- Tools menu

# Help menu





### **HELP**

#### **HOW TO SEARCH**

- User's Guide
- Query Syntax
- Fields Definition
- IPC/CPC classification fields
- Wildcard vs Stemming
- <u>Tutorials</u>
- Tips And Tricks
- Webinars

#### **PATENTSCOPE NEWS**

- New RSS feed in PATENTSCOPE [May 19, 2022]
- National Collection of Austria Now Available in PATENTSCOPE [May 2, 2022]
- Wildcards and fields in PATENTSCOPE [Mar 31, 2022]
- Milestone celebration: over 100 million patent documents in PATENTSCOPE [Jan 12, 2022]
- Search in PATENTSCOPE and access other services using the WIPO IP Portal widgets [Dec 6, 2021]

#### LATEST NEWSLETTER

## DATA COVERAGE

- PCT applications
- PCT national phase entry
- National collections
- Global Dossier public
- Chemical documents
- Standard ST37 Authority Definition File

## **NATIONAL COLLECTIONS - DATA COVERAGE**

Offices for which PCT national phase information is available

#### Updated: June 7, 2022

Country	Latest Biblio	Update Frequency	Biblio Data	Abstract	Chemical Data	Chemical indexed	Doc images	OCR (full-te	xt] Indexed	Nb records
PCT	07.06.2022	Daily	19.10.1978 - 02.06.2022		11.01.1979 - 27.05.2022	891,913	4,333,772	Total: Arabic: German: English: Spanish: French: Japanese: Korean: Portuguese Russian: Chinese:	4,273,770 198 417,837 2,414,045 28,874 140,530 714,226 141,474 21,738 389,130	4,333,772
African Regional Intellectual Property Organization (ARIPO)			03.07.1985 - 28.07.2008				1,676	<b>Total:</b> English:	<b>1,671</b> 1,671	1,868
Argentina	05.05.2022	Monthly	11.02.1965 - 27.04.2022				9,741	Total: Spanish:	<b>8,906</b> 8,906	171,672

PCT: 4,333,772

Offices: 99,701,139

Overall: 104,034,911

# Searching in filing languages

Arabic, Bulgarian, Cambodian, Chinese, Danish, English, Estonian, French, German, Greek, Hebrew, Italian, Japanese, Korean, Laotian, Portuguese, Romanian, Russian, Spanish, Thai, Vietnamese, etc.


## 简单检索

您可以通过PATENTSCOPE检索104百万专利文件,其中包含4.3百万已公布的国际专利申请(PCT)。具体信息

PCT公布22/2022 (02.06.2022) 现可从<u>这里查阅。下一次PCT公布23/2022日期为09.06.2022。多</u>

查看新的PATENTSCOPE功能: CPC、NPL、专利族......

支持新冠肺炎创新工作的检索功能




### **HOW TO SEARCH**

- User's Guide
- Query Syntax
- Fields Definition
- IPC/CPC classification fields
- Wildcard vs Stemming
- <u>Tutorials</u>
- Tips And Tricks
- Webinars

## **TIPS AND TRICKS**

Date ▼	Title \$
07.06.2022	OR NEAR combined
31.05.2022	Sequence Listings
24.05.2022	PCT monitoring
16.05.2022	RSS feed
10.05.2022	<u>Operators ANDNOT NOT</u>
03.05.2022	what s new may 2022
26.04.2022	Download result list
19.04.2022	<u>Crosslingual tool</u>
12.04.2022	Contact
05.04.2022	<u>NPL</u>
29.03.2022	Wildcards
22.03.2022	covid19 Index



0:03 / 0:56 🜓 ——— 💢

### **HOW TO SEARCH**

- User's Guide
- Query Syntax
- Fields Definition
- IPC/CPC classification fields
- Wildcard vs Stemming
- <u>Tutorials</u>
- Tips And Tricks
- Webinars

# **Syntax**

Fields
You can search any field by typing the field name followed by a colon ":" or "/" and then the term you are looking for. Examples:  EN_TI:("wind turbine" AND electric) solar
Since EN_ALL is the default field, the field indicator is not required.
Note: The field is only valid for the term that it directly precedes, so the query
EN_TI:["wind turbine" AND electric] solar
Will only find "wind turbine" AND electric in the title field. It will find "solar" in the default field (in this case the EN_ALL field).
Note:The seperator between the name of the field and its value can be either ":" or "/".

#### Wildcard Searches

It supports single and multiple character wildcard searches within single terms. To perform a single character wildcard search use the "?" symbol. To perform a multiple character wildcard search use the "\*" symbol.

The single character wildcard search looks for terms that match that with the single character replaced. For example, to search for "text" or "test" you can use the search:

te?t

Multiple character wildcard searches looks for 0 or more characters. For example, to search for electric, electrical or electricity, you can use the search:

✓ electric\*

You can also use the wildcard searches in the middle of a term.

✓ elec\*ty

Note: All the wildcard queries are executed against non-stemmed fields: EN\_TI\_S/mot\* is converted to EN\_TI/mot\*

Note: PhraseQuery keeps the stemming option if no wildcards are found: EN\_TI/"electric motor" is stemmed while EN\_TI\_S/"electric mot\*" is converted to EN\_TI/"electric mot\*"

Note: use ALLNUM fields if you do queries using IDs like PCT/US/2009/0\*, otherwise using the default field EN\_ALL then query should be formulated like: [PCT US/2009/0\*]

✓ ALLNUM:PCT/US/2009/0\*

Note: You cannot use a  $\ast$  or ? symbol as the first character of a search.

Note: You may use up to seven wildcards if you are a logged-in user, but only three if you are not.

# Unlimited keywords - operators

- Unlimited keywords
- Supported operators:
  - AND
  - OR
  - ANDNOT
  - NOT
  - BEFORE
  - NEAR


# Fields

### **NATIONAL COLLECTIONS - FIELDS DEFINITION**

View Fields Diagram

_				
Symbol \$	Name \$	Help	Type ≎	Stemmed \$
AAD	Applicant Address	✓ AAD:(London)	text	false
AADC	Applicant Address Country	AADC:(US)	string	false
АВ	Abstract	AB:("electric car" OR "voiture electrique"~50)	text	true
AD	Application Date	<ul> <li>∠ AD:(2010)</li> <li>∠ AD:(201007)</li> <li>∠ AD:(20100715)</li> <li>∠ AD:([01.01.2000 TO 01.01.2005])</li> </ul>	date	false
ALL	All fields	<ul> <li>∠ ALL:("electric car" OR "voiture electrique"~50')</li> <li>∠ ALL:("electric car"~50)</li> <li>∠ ALL:(elec*ty)</li> </ul>	text	false
ALLNUM	All Numbers and IDs	The entered value is searched against the application number, the PCT publication number, the national publication number and the priority number  ALLNUM:(US200500*)	string	false

### ADVANCED SEARCH -



Chinese Description

Danish Description

Description

Chemical

**English Abstract** 

English All

**English Claims** 

**English Description** 

☐ Include NPL

#### Samples of searches:

wind turbine - general searches, looking everywhere


EN\_ALLTXT: (wind turbine) - all the text fields are searched, the relevance of top results is of high quality

ALLNAMES: [Mao Yumin] - looking for applicant, inventor, agent names

ALLNUM: [DK 2008 123] - looking for IDs, WO, PCT numbers

Reset

Search




## How to search

### **HOW TO SEARCH**


- User's Guide
- Query Syntax
- Fields Definition
- IPC/CPC classification fields
- Wildcard vs Stemming
- Tutorials
- <u>Tips And Tricks</u>
- Webinars

# Stemming



# Stemming

- Stem = stemming
- Process that removes common endings from words.



# Stemming

no dictionary includes the necessary technical terms to express patent concepts



- Porter Stemming Algorithm finds words that contain common roots
- Save time and effort

# **WILDCARD VS STEMMING**


This page shows the different result a wildcard matches as opposed to using the stemming option		
Enter a word		
Compare to		
Stemming	Wildcard *	
No records found.	No records found.	

Enter a word electric	·
Compare to	
Stemming electric	Wildcard electric*
electric	electric
electrical	electrical
electrically	electrically
electricity	electricity
electrics	electrician
electricly	electricelectric
electrization	electrico
electr	electrica
	electrics
	electricians
	electricly
	electricos
	electricas
	electricamente
	electricty
	electricallyinsulating
	electricalsignal
	electricaly


# Where to find what?

- Help menu
- Search menu
- Tools menu

# Search menu





# Search menu



# Search: Simple

## SIMPLE SEARCH






# Search




- biomarker cancer biomarker «cancer biomarker»
- biomarker NEAR cancer
- biomarker NEAR cancer AND IC:A


# Search



# Search: Field Combination



# Search menu



# Advanced search

- ☐ Unlimited number of search terms
- ☐ Boolean operators: AND, OR, NOT, ANDNOT
- ☐ Proximity: NEAR, BEFORE
- ☐ Range operators: [...TO...], {...TO...}
- ☐ Wildcards: ?, \*
- Weighting factor: ^
- ☐ Query assistant



## ADVANCED SEARCH -

✔ Please enter a valid field... [or use UP/DOWN keys, and TAB or ENTER to select] applic Applicant Address Applicant Address Country Applicant All Data Applicant Name Applicant Nationality Applicant Residence **Application Date Application Number** Main Applicant Name National Phase Application Number Reset Search

# ADVANCED SEARCH -



C: CHEMISTRY; METALLURGY

C01: INORGANIC CHEMISTRY

CO2: TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE

C03: GLASS: MINERAL OR SLAG WOOL

CO4: CEMENTS: CONCRETE: ARTIFICIAL STONE: CERAMICS: REFRACTORIES

C05: FERTILISERS; MANUFACTURE THEREOF


C06: EXPLOSIVES: MATCHES

C07: ORGANIC CHEMISTRY

C08: ORGANIC MACROMOLECULAR COMPOUNDS: THEIR PREPARATION OR CHEMICAL WORKING-UP: COMPOSITIONS BASED THEREON

CO9: DYES: PAINTS: POLISHES: NATURAL RESINS: ADHESIVES: COMPOSITIONS NOT OTHERWISE PROVIDED FOR: APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR

C10: PETROLEUM, GAS OR COKE INDUSTRIES; TECHNICAL GASES CONTAINING CARBON MONOXIDE; FUELS; LUBRICANTS; PEAT



Sort: Pub Date Desc ▼ Per page: 100 ▼ View: All+Image ▼

762 results Offices all Languages all Stemming true Single Family Member false Include NPL false

< 1/8 ▼ >

Download ▼ Machine translation ▼

1. W0/2021/126999 USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR

Int.Class G01N 33/574 (?) Appl.No PCT/US2020/065341 Applicant MERCK SHARP & DOHME CORP. Inventor NICHOLSON, Benjamin

The present invention includes methods of identifying a patient who will likely be responsive to treatment with a protein arginine N-methyltransferase 5 inhibitor, or a pharmaceutically acceptable salt thereof, and methods of treating the same.

2. WO/2021/119759 OVARIAN CANCER BIOMARKER DETECTION THROUGH OVARIAN BLOOD SAMPLING

Int.Class G01N 33/574 Appl.No PCT/AU2020/051400 Applicant UNIVERSITY OF SOUTH AUSTRALIA Inventor HOFFMANN, Peter

The present invention is directed to a biological marker of ovarian cancer, including early stage ovarian cancer. Specifically, the present invention provides methods for detecting ovarian cancer in a subject which include detecting an expression level of the biological marker junction plakoglobin in blood of the subject. An expression level of junction plakoglobin that is higher than a reference expression level for junction plakoglobin indicates that the subject has ovarian cancer. Methods of identifying a subject having ovarian cancer and methods of determining if a subject is susceptible to developing ovarian cancer are also provided based on detecting the expression level of junction plakoglobin in blood of the subject. The present invention also extends to methods of treatment of ovarian cancer together with methods of screening a candidate therapeutic agent for use in treating ovarian cancer. Furthermore, compositions and kits for detecting ovarian cancer in a subject are provided, as well as a method of identifying a biomarker for a cancer, including ovarian cancer.



3. 3839513 USE OF DNA-TRANSCRIPTION FACTOR COMPLEXES FOR CANCER DETECTION

Int.Class 601N 33/574 (?) Appl.No 20210821 Applicant BELGIAN VOLITION SPRL Inventor MICALLEF JACOB VINCENT

The invention relates to the use of tissue specific transcription factor-nucleosome adducts or transcription cofactor-nucleosome adducts as biomarkers in a biological fluid for the detection or diagnosis of a cancer in a subject. The invention further relates to using said tissue specific transcription factor or cofactor adducts to identify the site of development of a cancer in a subject.




FIGURE 1

4. 20210181184 METHODS FOR TREATING MULTIPLE MYELOMA AND THE USE OF COMPANION BIOMARKERS FOR 4-[4-[4-[([2-[2,6-DIOXOPIPERIDIN-3-YL]-1-OXOISOINDOLIN-4-YL]OXY]METHYL]BENZYL]PIPERAZIN-1-YL]-

3-FLUOROBENZONITRILE

Int.Class G01N 33/50 (?) Appl.No 17173176 Applicant Celgene Corporation Inventor Maria Soraya Carrancio Anton



## 1. US20180188252 - METHODS FOR DIAGNOSIS AND PROGNOSIS OF EPITHELIAL CANCERS



PermaLink Machine translation ▼

National Biblio. Data Description Claims Drawings Patent Family Compounds Documents

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[EN]

### Claims

- 1. A method for facilitating the diagnosis of a patient for a cancer of epithelial origin comprising:
- a. obtaining a biological sample from the patient; and
- b. detecting the presence or absence of at least one epithelial cancer biomarker in the biological sample,

wherein the presence of at least one epithelial cancer biomarker is indicative of cancer of epithelial origin, and wherein the epithelial cancer biomarker is selected from the group consisting of Cystatin B, Chaperonin 10, and Profilin.

- 2. A method for diagnosing a cancer of epithelial origin in a patient comprising:
- a. measuring at least one epithelial cancer biomarker levels present in a biological sample obtained from the patient, a test sample;
- b. comparing the level of at least one epithelial cancer biomarker in the test sample with the level of epithelial cancer biomarker present in a control sample;


wherein a higher level of at least one epithelial cancer biomarker in the test sample as compared to the level of epithelial cancer biomarker in the control sample is indicative of cancer of epithelial origin, and wherein the epithelial cancer biomarker is selected from the group consisting of Cystatin B, Chaperonin 10, and Profilin.

- 3. The method of claim 1, wherein the cancer of epithelial origin is selected from the group consisting of breast cancer, basal cell carcinoma, adenocarcinoma, gastrointestinal cancer, lip cancer, mouth cancer, esophageal cancer, small bowel cancer, stomach cancer, colon cancer, liver cancer, bladder cancer, pancreas cancer, overy cancer, cervical cancer, lung cancer, stomach cancer, and renal cell carcinoma.
- 4-6. (canceled)
- 7. The method of claim 1, wherein the biological sample is urine.
- 8. The method of claim 1, wherein the presence or absence of at least

one epithelial cancer biomarker or Cystatin B is detected using an antibody-based binding moiety which specifically binds to at least one epithelial cancer biomarker or to Cystatin B.


- 9. The method of claim 2, wherein the level of at least one
- epithelial cancer biomarker or Cystatin B is measured by measuring the protein level of at least one epithelial cancer biomarker protein or Cystatin B.
- 10. The method of claim 9, wherein the protein level of epithelial cancer biomarker or level of Cystatin B is measured by a method comprising the steps of:
- a. contacting the test sample, or preparation thereof, with an antibody-based binding moiety which specifically binds the epithelial cancer biomarker or to Cystatin B to form an antibody-epithelial cancer biomarker complex; and
- b. detecting the presence of the complex, thereby measuring the level of epithelial cancer biomarker present.
- 11. The method according to claim 8, wherein the antibody-based binding moiety is labeled with a detectable label.
- 12. The method according to claim 11, wherein the label is selected from the group consisting of a radioactive label, a hapten label, a fluorescent label, and an enzymatic label.
- 13. The method according to claim 8, wherein the antibody-based binding moiety is an antibody.
- 14. The method according to claim 13, wherein the antibody is an monoclonal antibody.
- 15-19. (canceled
- 20. The method of claim 2, wherein the cancer of epithelial origin is selected from the group consisting of breast cancer, basal cell carcinoma, adenocarcinoma, gastrointestinal cancer, lip cancer, mouth cancer, esophageal cancer, small bowel cancer, stomach cancer, colon cancer, liver cancer, bladder cancer, pancreas cancer, overy cancer, cervical cancer, liver cancer, and renal cell carcinoma.
- 21. The method according to claim 10, wherein the antibody-based binding moiety is labeled with a detectable label.
- 22. The method according to claim 10, wherein the antibody-based binding moiety is an antibody.

# Search menu



# Search: CLIR

## **CROSS LINGUAL EXPANSION -**



Search

# **CLIR**

EN AB:("toancer biomarker") OR FR AB:("biomarcador cancer") OR FR AB:("biomarcador cancer") OR DE AB:("Krebsbiomarker") OR ES AB:("biomarcador cancer"-22) OR PT AB:("biomarcador cancer"-22 OR "biomarcador cancer") OR DE AB:("Krebsbiomarker") OR DE AB:("biomarcador cancer") OR DE AB:("b 品固品田 2,090 results Offices all Languages all Stemming true Single Family Member false Include NPL false **FULL QUERY** EN\_AB:("cancer biomarker") OR FR\_AB:("biomarcador cancer" > 22 OR "biomarcador cancer" > 22 OR "biomarc "biomarcardor câncer"~22) OR JA\_AB:("ガン バイオマーカ"~22 OR "ガン バイオ"~22 OR "ガン マーカー"~22 OR "海にイオマーカー" OR "の稿 バイオマーカ"~22 OR "発稿 バイオマーカ"~22 OR "ガン 生物指標"~22 OR "の稿 バイオ"~22 OR "発稿 バイ オ"~22) OR RU AB:("海底 化生物标记物"~22 OR "海底 биомаркер"~22 OR "海底 биомаркеров мелкоклеточного"~22 OR "рака биомаркерные"~22) OR ZH AB:("海底 生物标記"~22 OR "海底 化生物标记物"~22 OR "海底 卵巢"~22) OR KO AB:("바이오마커 암"~22 OR "바이오마 커 진단용 마커"~22) OR IT\_AB:("cancer biomarkōr"~22 OR "cance biomarcatore"~22 OR "neoplasie biomarcatore"~22) OR SV\_AB:("cancer biomarkōr"~22 OR "kancer biomarkōr"~22) OR DA\_AB:("cancer biomarkōr"~22) < 1/21 ▼ > Sort: Relevance ▼ Per page: 100 ▼ View: All+Image ▼ Download ▼ Machine translation ▼ 1. 2014513949 患者における癌の診断方法 JP - 19.06.2014 Int.Class C120 1/48 ② Appl.No 2014508513 Applicant トラクソン・リミテッド・ライアビリティ・カンパニー Inventor ロバート・パスカス 本願は、ある特定の癌パイオマーカーの存在、活性および/または濃度を判定するための方法、ならびに癌の存在の判定におけるその使用に関する。 2. W0/2021/114201 CANCER BIOMARKER AND USE WO - 17 08 2021 Int.Class C120 1/6886 (2) Appl.No PCT/CN2019/125011 Applicant SUZHOU INSTITUTE OF BIOMEDICAL ENGINEERING AND TECHNOLOGY CHINESE ACADEMY OF SCIENCES Inventor GAO, Shan Provided are a cancer biomarker and use. The cancer biomarker comprises a programmed cell death protein PD-1, a gene PDCD1, and/or PD-1 mRNA in tumor cells; pD-1 is subjected to broad-spectrum expression in tumor cells and plays a role in inhibiting the growth of the tumor cells. The cancer biomarker is used for predicting, evaluating or identifying the effectiveness of a PD-1 antibody on treatment of tumor patients with immunodeficiency or immunocompromised tumor patients. A tumor patient who is not suitable for PD-1 antibody treatment is predicted; more effective medication and therapy selection suggestions are provided for tumor patients.

### 1. 2014513949 METHOD FOR DIAGNOSING CANCER IN PATIENT

Int.Class C12Q 1/48 ② Appl.No 2014506513 Applicant トラクソン・リミテッド・ライアピリティ・カンパニー Inventor ロバート・パスカス

The present application relates to a method for determining the presence, activity and/or concentration of a particular cancer biomarker, as well as its use in determining the presence of cancer



NO IMAGE AVAILABLE

### 2. W0/2021/114201 CANCER BIOMARKER AND USE

Int.Class C12Q 1/6888 (7) Appl.No PCT/CN2019/125011 Applicant SUZHOU INSTITUTE OF BIOMEDICAL ENGINEERING AND TECHNOLOGY CHINESE ACADEMY OF SCIENCES Inventor GAO, Shan

Provided are a cancer biomarker and use. The cancer biomarker comprises a programmed cell death protein PD-1, a gene PDCD1, and/or PD-1 mRNA in tumor cells; pD-1 is subjected to broad-spectrum expression in tumor cells and plays a role in inhibiting the growth of the tumor cells. The cancer biomarker is used for predicting, evaluating or identifying the effectiveness of a PD-1 antibody on treatment of tumor patients with immunodeficiency or immunocompromised tumor patients. A tumor patient who is not suitable for PD-1 antibody treatment is predicted; more effective medication and therapy selection suggestions are provided for tumor patients.

A CONTROL OF THE PROPERTY OF T

All (Autorite office)

Shad year office

Citic year office

Poster year office

Poster year office

Strong year office

Strong year office

Strong year office

It for year of year office

It for year office

It for year office

It for year of yea

### 3. 2014530355 IMMUNOLOGICAL PROTEIN, PATHOGENIC AND MICROBIAL FACTOR, AND DEVICE AND METHOD FOR DETECTING AND QUANTIFYING CELL

Int.Class G01N 27/74 ?? Appl.No 2014531827 Applicant カーネギー メロン ユニパーシティ Inventor ガンディーニー, アルベルト

The present invention provides a method and apparatus for detecting and quantifying the concentration of magnetically responsive microbeads dispersed in a liquid sample. Also provided are a method for detecting and quantifying the concentration of an analyte in a sample medium using magnetically responsive microbeads coated with an antigen-specific antibody, and a microfluidic immunoassay PSCREEN ™ device.. The methods and apparatus of the present invention allow quantification of a wide variety of analytes, such as proteins, protein fragments, antibodies, antibody fragments, peptides, RNA, RNA fragments, CD4 +, CD8 + cells, cancer biomarkers such as malaria-infected red blood cells, cancer cells, prostate-specific antigens, and other cancer biomarkers, viruses, bacteria, and other pathogenic factors. Out-of -. A wide variety of applications for care diagnosis are provided COPYRIGHT

JP - 17.11.2014

WO - 17.06.2021

NO IMAGE AVAILABLE

### 4. 2011521897 PREFECTIN -1 TARGETING AGENT FOR DETECTION AND TREATMENT OF PANCREATIC TUBE ADENOCARCINOMA

Int.Class CO7K 7/06 ② Appl.No 2011505127 Applicant ザ ジェネラル ホスピタル コーポレイション Inventor ケリー、キンバリー

Compositions and methods for cancer cell biomarkers, such as pancreatic duct adenocarcinoma (PDAC) cell biomarkers, and binding molecules for cancer (eg. PDAC) diagnostic and therapeutic binding molecules are described herein. A "available" proteome identification method for cancer biomarker identification, such as a PDAC biomarker, is disclosed. Further provided is an imaging composition comprising magnetic fluorescent nanoparticles conjugated with a peptide ligand for PDAC identification.


JP - 28.07.2011



5. 2008529008 BIOMARKER FOR BLADDER CANCER


JP-31.07.2008

# Search menu



# Chemical search

## CHEMICAL COMPOUNDS SEARCH -



CHEM:(BSYNRYMUTXBXSQ-UHFFFAOYSA-N)

7,100 results Offices all Languages all Stemming tru

Single Family Member false Include NPL false

少 幣 🛭 幣 □

Download ▼ Machine translation ▼

JP - 24.11.2017

Sort: Relevance ▼ Perpage: 100 ▼ View: All+Image ▼

⟨ 1/1,971 ▼ ⟩

Int.Class G01N 33/49 (?) Appl.No 2017145031 Applicant JNC CORP Inventor WILLIAM M TROLIO

2017207510 DUAL ANTI-PLATELET MEDICATION/ASPIRIN RESPONSE AND REACTIVITY TEST USING SYNTHETIC COLLAGEN

PROBLEM TO BE SOLVED: To provide methods of determining anti-platelet medication sensitivity of platelets of an individual without using an animal-derived collagen as an agonist when the individual is on a dual anti-platelet therapy of aspirin and anti-platelet medication.

MEANS: A method of determining anti-platelet medication sensitivity of platelets of an individual who is on a dual anti-platelet therapy of aspirin and anti-platelet medication is provided, which involves performing a Light Transmission Aggregometry Assay (LTAA) using synthetic self-assembling human type I collagen containing a polypeptide having a peptide fragment represented by a formula (I), where X represents Hyp, and n represents an integer in a range of 20 to 250.

SELECTED DRAWING: None

COPYRIGHT: [C]2018,JP0&INPIT

2. 2015528567 合成コラーゲンを用いる二重抗血小板薬/アスピリン応答および反応性試験

Int.Class G01N 33/49 ⑦ Appl.No 2015526805 Applicant JNC株式会社 Inventor ウィリアム, エム・トロリオ

本発明は、合成自己組織化ヒトI型コラーゲンを用い、光透過型凝集測定アッセイ(LTAA)またはフローサイトメトリーを用いることなどによる機能性血小板凝集を測定する試験、個人がアスピリンと抗血小板薬との二重抗血/ 板瘴法を受けている場合に個人の血小板の抗血小板薬感受性および残留血小板活性状態を予測ならびに測定する方法、ならびに、これらのアッセイおよび方法において有用であるキットを提供する。


JP - 28.09.2015

3. WO/2014/025685 DUAL ANTI-PLATELET MEDICATION/ASPIRIN RESPONSE AND REACTIVITY TEST USING SYNTHETIC COLLAGEN

Int.Class C12Q 1/56 (?) Appl.No PCT/US2013/053612 Applicant JNC CORPORATION Inventor TROLIO, William M.


The present invention provides tests that measures functional platelet aggregation such as by using Light Transmission Aggregometry Assays (LTAAs) or flow cytometry, using synthetic, self-assembling human type I collagen, methods of predicting and measuring an individual's platelet anti-platelet medication sensitivity and residual platelet activity status when the individual is on a dual anti-platelet therapy of aspirin and anti-platelet medication and kits useful in the assays and methods.

WO - 13.02.2014



4. 2017506252 吸入用の乾燥粉末製剤 JP - 02.03.2017

Int Class ABTK 31/B18 ② Anni No. 2018553558 Anniirant オティトピック インコーボレイテッド Inventor セディディーカンビズ



\_본 발명은 CAPRIN- 1을 종양 마커로 하는 암의 검출 방법에 관한 것이다.

배경기술

\_암은 전체 사망 원인의 제 1위를 차지하는 질환이고, 현재 행해지고 있는 치료는 수술 요법을 주체로 방사선 요법과 화학 요법을 조합시킨 것이다. 지금까지의 의료 기술의 진보에 의해, 암종에 따라서는 조기 발견할 수 있으면 고칠 수 있는 가능성이 높은 질환이 되고 있다. 그 때문에, 암환자의 체력적, 경제적 부담이 없고, 간편하게 검사할 수 있는 암의 검출 방법이 요구되고 있다.

\_최근에는, 종양 마커 등의 종양 생산물을 측정하는 방법이 보급되어 왔다. 종양 생산물이란, 종양에 관련되는 항원, 효소, 특정 단백질, 대사산물, 종양 유전자, 종양 유전자 생산물 및 종양 억제 유전자 등을 가리키고, 암태아성 항원 CEA, 당 단백질 CA19-9, 전립선 특이 항원 PSA, 갑상선에서 생산되는 펩티드 호르몬인 칼시토닌 등이 일부의 암에서 종양 마커로서 암진단에 활용되고 있다. 그러나, 다른 많은 암종에 있어서는 암진단에 유용한 종양 마커는 존재하지 않는다. 또한, 현재 알려져 있는 종양 마커의 대부분은 체액 중에 극히 미량[pg/mL 오더 정도]밖에 존재하지 않기 때문에, 그들을 검출하기 위해서는 고감도한 측정법이나 특수한 기술을 필요로 한다. 이러한 현재 상황 중에서, 각종 암을 간편한 조작으로 고감도로 검출할 수 있는 신규한 암 검사 수단을 제공할 수 있으면, 각종 암에 대한 진단 용도가 열린다고 기대된다.

\_한편, 최근 새로운 수술법의 개발이나 새로운 항암제의 발견에도 불구하고, 일부 암을 제외하고 대부분의 암에서는 효과적인 암 진단 기술이 확립되어 있지 않다. 그러므로, 암을 조기에 발견할 수 없고, 암의 치료 성적은 그다지 향상되지 않은 것이 현재 상황이다.

\_최근, 분자생물학이나 암면역학의 진보에 의해, 암에 특이적으로 반응하는 항체나, 암화나 암의 악화에 관련되는 암 항원에 대한 분자 표적약 등, 암 항원류를 타깃으로 한 특이적 암 치료법에의 기대가 높아지고 있다. 그 중에서도, 암세포 상의 항원 단백질을 표적으로 한 암을 치료하기 위한 항체 의약이 복수 상시되어 암 치료에 사용되고 있다. 항체 의약은 암 특이적 치료약으로서 일정 약효를 얻을 수 있으므로 주목받고 있지만, 표적이되는 항원 단백질의 대부분은 정상세포에도 발현되는 것이고, 항체 투여의 결과, 암세포뿐만 아니라 항원이 발현되는 정상세포도 장해되어버려, 그 결과 생기는 부작용이 문제가 되고 있다. 또한, 암환자에 의해 병인은 다양하기 때문에 암 치료의 효과는 개인차가 매우 크다. 예를 들면, 수술, 화학 요법 또는 방사선 요법에 있어서, 암의 진행 단계에 의해 그 치료 및 예후는 크게 좌우된다. 개체의 다양성에 의해, 동일한 암 치료약에 대해서도 개개인으로 다른 감수성을 가진다는 것이 알려져 있고, 어떤 환자에 유효한 약이 다른 환자에게도 유효하다고는 할 수 없다.

\_그래서, 미리 환자의 질환 관련 유전자나 단백질의 발현을 측정하고, 어떤 특정 약품이 특정 유전자 또는 단백질을 발현하고 있는 암환자에 대하여 유효할 것인지 아닌지를 평가한 후에, 그 암환자에의 치료약의 투여 결정이 이루어지고 있다. 구체적으로는, 어느 종류의 암에 대한 질환 관련 유전자나 단백질을 측정하는 검출법을 사용하여, 임상 현장에서 암환자 유래의 시료, 예를 들면 혈청이나 조직 중에 암 항원이 존재하는지 아닌지를 검사한 후에 암 항원 특이적인 치료약의 투여 결정이 이르어지고 있다. 예를 들며 대장안 화자의 암조직을 면역 조직 화학 염색 EGFR 검출법 [EGFRpharm[DAKO Corporation]]에 의해 평가하고, 대장암에 있어서의 얼비통스의 유효성을 예측한 후에 얼비통스의 투여를 결정 음면 조직화학 염색 Her2검출법 [하십 테스트]에 의해 평가하고, 유방암에 있어서의 허셉틴의 유효성을 예측한 후에.

비툭스의 유효성을 예측한 후에 얼비툭스의 투여를 결정 허셉틴의 적용을 결정하고 있다.

\_그런데, 반려동물은 가족의 일원으로서 사육되고, 기르는 것이 알려져 있다.

대표적인 반려동물인 개는 인간과 비교하여 7배 빨리 나 종 등의 혼합백신이 일반적으로 보급되고, 개 파보바이 렙토스피라병이라는 치사율이 높은 감염증이 감소했다 일로를 걷고 있다. 미국에서는 1년에 약 400만마리의 개기 때문에 발견이 늦어, 종양이 커지고 처음으로 주인이 때문에, 수의사가 악성이라고 판단했을 경우에는 수술적실시할 필요가 있다. 수술 후 즉시 항암제 치료를 시작하

l는 경우가 많다. 그 때문에, 반려동물의 암 감염에 의해, 기르는 주인이 장래 암을 발병할 위험성이 높은 것을 예측할 수 있

유전자나 단백질을 측정하는 검출법이 존재하면, 지금까지 보다 효과적인 지료가 가능하게 되어 주인에게도 수의사에 있어서도 메리트가 크다.

\_Cytoplasmic-and proliferation-associated protein 1[ CAPRIN- 1]은 휴지기의 정상세포가 활성화나 세포분열을 일으킬 때에 발현되고, 또한 세포내에서 RNA와 세포내 스트레스 과립을 형성하여 mRNA의 수송, 번역의 제어에 관여하는 것 등이 알려져 있는 세포내 단백질이다. 한편으로, 본 발명자들은 유방암세포의 막 표면에 CAPRIN- 1이 고발현하고 있는지, CAPRIN- 1에 대한 항체가 유방암세포에 대하여 강한 항종양 효과를 발휘하는지를 발혀냈다[특허문헌 1]. 또한, 세포 표면에 발현하고 있는 CAPRIN- 1에 결합하는 항체를 사용하여, 환자에 유래하는 시료 중의 CAPRIN- 1의 발현을 측정함으로써, 암의 검출 및 암의 악성도를 평가할 수 있는 것이 보고되고 있다 즉, 세포막 단백질의 하나인 CAPRIN- 1은 암 치료 등의 타깃이 될 수 있는 것이 기재되어 있다. 한편 상술한 바와 같이, 암환자의 다양성으로부터 CAPRIN- 1을 표적으로 한 치료약, 예를 들면 항체의 투여를 결정하기 위해서는 미리 암환자 유래 시료 중의 CAPRIN- 1의 발현을 검증할 필요가 있다. 그러나, 이와 같이 특이적인 치료약을 적용하기 위한 CAPRIN- 1의 검출 방법에 관한 보고는 없고, 또한 암환자 시료를 사용한 암을 검출하는 시약은 존재하지 않는다.

선행기술문헌

특허문헌

\_[특허문헌 0001] W02010/016526

[특허문헌 0002] W02010/016527

# Result list

EN AB:(biomarker NEAR10 cancer)

11 4,418 results Offices all Languages all Stemming true Single Family Member false Include NPL false

少界 图 帝 田

Sort: Relevance ▼ Per page: 100 ▼ View: All+Image ▼

< 1/45 ▼ >


Download ▼ Machine translation ▼

KR - 29.08.2017

1020170097956 METHOD FOR SCREENING CANCER BIOMARKERS BY USING CAPILLARY WESTERN BLOT ASSAY

Int.Class G01N 33/574 (?) Appl.No 1020160019700 Applicant EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION Inventor SHEEN, YHUN YHONG

The present invention relates to a method for screening cancer biomarkers or cancer metastasis biomarkers using capillary western blot assay. According to the present invention, cancer biomarkers or cancer metastasis biomarkers can be rapidly and precisely screened. Accordingly, the method can be used for developing biomarkers useful for initial diagnosis and clinical stage judgment of cancer. COPYRIGHT KIPO 2017



2. 20150072890 METHODS AND COMPOSITIONS FOR AIDING IN THE DETECTION OF LUNG CANCER

Int.Class C12Q 1/68 ? Appl.No 14483503 Applicant William James Inventor William James

panel without the miRNA biomarkers.

A lung cancer biomarker panel comprising an microRNA (miRNA) lung cancer biomarker and at least one additional lung cancer biomarker selected from a tumor protein (TP) lung cancer biomarker and/or a autoantibody (AAB) lung cancer biomarker is provided herein and methods for screening patients for lung cancer. The present lung cancer biomarker panel provides an improvement in sensitivity and diagnostic accuracy for lung cancer as compared to a lung cancer biomarker



3. WO/2020/160108 LIPID BIOMARKERS FOR CANCER SCREENING AND MONITORING

Int.Class G01N 33/92 O Appl.No PCT/US2020/015617 Applicant ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA Inventor CHILTON, Floyd H.

Provided herein are biomarkers for cancer screening and monitoring. In particular, provided herein are lipid biomarkers for cancer diagnosis, prognosis, risk, and response to treatment.

WO - 06.08.2020


WO - 15.06.2017



4. W0/2017/099414 METHOD FOR DISCOVERY OF MICRORNA BIOMARKER FOR CANCER DIAGNOSIS, AND USE THEREOF

Int.Class 606F 19/18 ? Appl.No PCT/KR2016/013975 Applicant LG ELECTRONICS INC. Inventor LEE, Jaehoon

The present invention relates to a method for discovery of a novel miRNA biomarker for cancer diagnosis, a biomarker for diagnosis of bile duct cancer or pancreatic cancer which has been discovered through the method for discovery of a biomarker, a method for diagnosing cancer, comprising a step in which cancer is diagnosed when f(x) > 0 by substitution of the expression level of the miRNA biomarker, which is detected by the method for discovery of an miRNA biomarker for cancer diagnosis, in a sample into a novel SVM classifier function, a kit for diagnosing bile duct cancer or pancreatic cancer comprising the biomarker for diagnosing bile duct cancer or pancreatic cancer, and a computing device for performing a process of diagnosing cancer when f(x) > 0 as a result of a calculation by substitution of the expression level of an miRNA hipmarker, which is detected by the method for discovery of an miRNA hipmarker for cancer diagnosis, into the novel SVM





4. WO/2017/099414 METHOD FOR DISCOVERY OF MICRORNA BIOMARKER FOR CANCER DIAGNOSIS, AND USE THEREOF

Int.Class 606F 19/18 ? Appl.No PCT/KR2016/013975 Applicant LG ELECTRONICS INC. Inventor LEE, Jaehoon

The present invention relates to a method for discovery of a novel miRNA biomarker for cancer diagnosis, a biomarker for diagnosis of bile duct cancer or pancreatic cancer which has been discovered through the method for discovery of a biomarker, a method for diagnosing cancer, comprising a step in which cancer is diagnosed when fly > 0 by substitution of the expression level of the miRNA biomarker, which is detected by the method for discovery of an miRNA biomarker for diagnosing bile duct cancer comprising the biomarker for diagnosing bile duct cancer, and a computing device for performing a process of diagnosing cancer when flx! > 0 as a result of a calculation by substitution of the expression level of an miRNA biomarker, which is detected by the method for discovery of an miRNA biomarker for cancer diagnosis, into the novel SVM.

WO - 15.06.2017





# 11. W02021104442 - METHOD AND COMPOSITIONS FOR PREDICTING ANTI-CANCER EFFICACY OF COMPOUNDS TARGETING APOPTOSIS PATHWAY



PCT Biblio. Data Full Text Drawings ISR/W0SA/A17[2][a] National Phase Patent Family Notices Compounds Documents

Submit observation PermaLink Machine translation ▼

Publication Number

W0/2021/104442

**Publication Date** 

03.08.2021

International Application No.

PCT/CN2020/132191

International Filing Date

27.11.2020

IPC

ABIK 31/407 2008.01 ABIK 31/498 2008.01 C07D 487/10 2008.01 C07D 471/04 2008.01 C07D 401/14 2008.01 C120 1/88 2018.01

View more classifications

#### Applicants

ASCENTAGE PHARMA [SUZHOU] CO., LTD. [CN]/[CN]
Unit 701, Building B7, 218 Xinghu Street
Suzhou Industrial Park Suzhou, Jiangsu
215000, CN

ASCENTAGE PHARMA GROUP CORP LIMITED [CN]/[CN] 9/F, Wah Yuen Building 149 Queen' S Road Central Hong Kong, CN

#### Inventors

ZHAI, Yifan YANG, Dajun FANG, Douglas D. TAO, Ran

#### Agents

JUN HE LAW OFFICES 20/F, China Resources Building 8 Jianguomenbei Avenue Beijing 100005, CN

#### **Priority Data**

PCT/CN2019/121214 27.11.2019 CN

#### **Publication Language**

English (EN)

#### Filing Language

English (EN)

### **Designated States**

View all

#### Title

(EN) METHOD AND COMPOSITIONS FOR PREDICTING ANTI-CANCER EFFICACY OF COMPOUNDS TARGETING APOPTOSIS PATHWAY
IFRI MÉTHODE ET COMPOSITIONS POUR PRÉDIRE L'EFFICACITÉ ANTICANCÉREUSE DE COMPOSÉS CIBLANT LA VOIE DE L'APOPTOSE

#### Abstract

#### (EN)

Provided are biomarkers for predicting the efficacy of MDM2 inhibitor or Bcl-2/Bcl-xL dual inhibitors or Bcl-2 inhibitor in treating cancer patients. Also provided are compositions, e.g., kits, for evaluating gene levels of the biomarkers and methods of using such gene levels to predict a cancer patient's response to the MDM2 inhibitors or Bcl-2/Bcl-xL dual inhibitors or Bcl-2 inhibitor or Bcl-xL inhibitor. Such information can be used in determining prognosis and treatment options for cancer patients.

#### (FE

L'invention concerne des biomarqueurs pour prédire l'efficacité d'un inhibiteur de MDM2 ou de doubles inhibiteurs de Bcl -2/Bcl-xL ou d'un inhibiteur de Bcl-2 ou d'un inhibiteur de Bcl-xL dans le traitement de patients atteints de cancer. L'invention concerne également des compositions, par exemple, des kits, pour évaluer les niveaux de gênes des biomarqueurs et des méthodes d'utilisation de tels niveaux de gênes pour prédire une réponse d'un patient cancéreux aux inhibiteurs de MDM2 ou aux doubles inhibiteurs de Bcl-2/Bcl-xL ou à un inhibiteur de Bcl -2 ou à un inhibiteur de Bcl-xL. De telles informations peuvent être utilisées pour déterminer des options de pronostic et de traitement pour des patients atteints d'un cancer.

#### Also published as

CN112852959



### EN AB:(biomarker NEAR10 cancer)

4,418 results Offices all Languages all Stemming true Single Family Member false Include NPL false

Sort: Relevance ▼ Perpage: 100 ▼ View: All+Image ▼

( 1/45 ▼ )

Machine translation ▼

### 1. 1020170097956 METHOD FOR SCREENING CANCER BIOMARKERS BY USING CAPILLARY WESTERN BLOT ASSAY

Int.Class G01N 33/574 (7) Appl.No 1020160019700 Applicant EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION Inventor SHEEN, YHUN YHONG

The present invention relates to a method for screening cancer biomarkers or cancer metastasis biomarkers using capillary western blot assay. According to the present invention, cancer biomarkers or cancer metastasis rapidly and precisely screened. Accordingly, the method can be used for developing biomarkers useful for initial diagnosis and clinical stage judgment of cancer. COPYRIGHT KIPO 2017

Download ▼ 100 results KR - 29.08.2017 10.000 results

### 20150072890 METHODS AND COMPOSITIONS FOR AIDING IN THE DETECTION OF LUNG CANCER

Int.Class C12Q 1/68 ? Appl.No 14483503 Applicant William James Inventor William James

A lung cancer biomarker panel comprising an microRNA [miRNA] lung cancer biomarker and/or a autoantibody [AAB] lung cancer biomarker selected from a tumor protein [TP] lung cancer biomarker and/or a autoantibody [AAB] lung cancer biomarker. biomarker is provided herein and methods for screening patients for lung cancer. The present lung cancer biomarker panel provides an improvement in sensitivity and diagnostic accuracy for lung cancer as compared to a lung cancer biomarker panel without the miRNA biomarkers.

### 3. WO/2020/160108 LIPID BIOMARKERS FOR CANCER SCREENING AND MONITORING

Int.Class 601N 33/92 (?) Appl.No PCT/US2020/015617 Applicant ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA Inventor CHILTON, Floyd H.

Provided herein are biomarkers for cancer screening and monitoring. In particular, provided herein are lipid biomarkers for cancer diagnosis, prognosis, risk, and response to treatment.

WO - 06.08.2020

US - 12.03.2015



### 4. W0/2017/099414 METHOD FOR DISCOVERY OF MICRORNA BIOMARKER FOR CANCER DIAGNOSIS, AND USE THEREOF

Int.Class 606F 19/18 ? Appl.No PCT/KR2016/013975 Applicant LG ELECTRONICS INC. Inventor LEE, Jaehoon

The present invention relates to a method for discovery of a novel miRNA biomarker for cancer diagnosis, a biomarker for diagnosis of bile duct cancer or pancreatic cancer which has been discovered through the method for discovery of a biomarker, a method for diagnosing cancer, comprising a step in which cancer is diagnosed when f(x) > 0 by substitution of the expression level of the miRNA biomarker, which is detected by the method for discovery of an miRNA biomarker for cancer diagnosis, in a sample into a novel SVM classifier function, a kit for diagnosing bile duct cancer or pancreatic cancer comprising the biomarker for diagnosing bile duct cancer or pancreatic cancer, and a computing device for performing a process of diagnosing cancer when f(x) > 0 as a result of a calculation by substitution of the expression level of an miRNA biomarker, which is detected by the method for discovery of an miRNA biomarker for cancer diagnosis, into the proved SVM.



WO - 15.06.2017

### EN\_AB:(biomarker NEAR10 cancer)

Sort: Relevance ▼ Perpage: 100 ▼ View: All+Image ▼

4,418 results Offices all Languages all Stemming true Single Family Member false Include NPL false

< 1/45 ▼ >

9 W B




Download ▼ Machine translation ▼

KR - 29.08.2017

1020170097956 METHOD FOR SCREENING CANCER BIOMARKERS BY USING CAPILLARY WESTERN BLOT ASSAY

Int.Class G01N 33/574 (?) Appl.No 1020160019700 Applicant EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION Inventor SHEEN, YHUN YHONG

The present invention relates to a method for screening cancer biomarkers or cancer metastasis biomarkers using capillary western blot assay. According to the present invention, cancer biomarkers or cancer metastasis biomarkers can be rapidly and precisely screened. Accordingly, the method can be used for developing biomarkers useful for initial diagnosis and clinical stage judgment of cancer. COPYRIGHT KIPO 2017



US - 12.03.2015

2. 20150072890 METHODS AND COMPOSITIONS FOR AIDING IN THE DETECTION OF LUNG CANCER

panel without the miRNA biomarkers.

Int.Class C12Q 1/68 Appl.No 14483503 Applicant William James Inventor William James

A lung cancer biomarker panel comprising an microRNA [miRNA] lung cancer biomarker and at least one additional lung cancer biomarker selected from a tumor protein [TP] lung cancer biomarker and/or a autoantibody (AAB) lung cancer biomarker is provided herein and methods for screening patients for lung cancer. The present lung cancer biomarker panel provides an improvement in sensitivity and diagnostic accuracy for lung cancer as compared to a lung cancer biomarker



3. W0/2020/160108 LIPID BIOMARKERS FOR CANCER SCREENING AND MONITORING

Int.Class 601N 33/92 (?) Appl.No PCT/US2020/015617 Applicant ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA Inventor CHILTON, Floyd H.

Provided herein are biomarkers for cancer screening and monitoring. In particular, provided herein are lipid biomarkers for cancer diagnosis, prognosis, risk, and response to treatment.

WO - 06.08.2020



4. W0/2017/099414 METHOD FOR DISCOVERY OF MICRORNA BIOMARKER FOR CANCER DIAGNOSIS, AND USE THEREOF

Int.Class 608F 19/18 ? Appl.No PCT/KR2018/013975 Applicant LG ELECTRONICS INC. Inventor LEE, Jaehoon

The present invention relates to a method for discovery of a novel miRNA biomarker for cancer diagnosis, a biomarker for diagnosis of bile duct cancer or pancreatic cancer which has been discovered through the method for discovery of a biomarker, a method for diagnosing cancer, comprising a step in which cancer is diagnosed when f(x) > 0 by substitution of the expression level of the miRNA biomarker, which is detected by the method for discovery of an miRNA biomarker for cancer diagnosis, in a sample into a novel SVM classifier function, a kit for diagnosing bile duct cancer or pancreatic cancer or pancreatic cancer, and a computing device for performing a process of diagnosing cancer when f(x) > 0 as a result of a calculation by substitution of the expression level of an miRNA biomarker, which is detected by the method for discovery of an miRNA biomarker for cancer diagnosis, into the novel SVM.

WO - 15.06.2017

### EN CL:(biomarker NEAR10 cancer) AND DP:[2018 TO 2021]

Relevance ▼ 100 ▼ All+Image ▼

1776 results Offices all Languages all Stemming true Single Family Member false Include NPL false

Machine translation ▼

< 1/8 ▼ >

1. 20180188252 METHODS FOR DIAGNOSIS AND PROGNOSIS OF EPITHELIAL CANCERS

Int.Class G01N 33/574 (?) Appl.No 15875151 Applicant Children's Medical Center Corporation Inventor BRUCE R. ZETTER

The present invention is based on the discovery that three proteins, Cystatin B, Chaperonin 10, and Profilin are present in the urine of patients with bladder cancer, a cancer of epithelial origin. Accordingly, the present invention is directed to methods for prognostic evaluation of cancers of epithelial origin and to methods for facilitating diagnosis of cancers of epithelial origin

US - 05.07.2018



FIG. 1

### 2. 2020202066 METHODS AND COMPOSITIONS FOR DETECTING PANCREATIC CANCER

Int.Class 601N 33/574 (?) Appl.No 2020202086 Applicant Creatics LLC Inventor

The present invention relates to non-invasive methods for the diagnosis and prognosis of pancreatic cancer. In some embodiments, such methods and compositions relate to particular pancreatic cancer biomarkers and combinations thereof

AU - 09.04.2020

US - 04.10.2018

Sample processing for MS analysis



### 3. 20180282815 COLORECTAL CANCER SCREENING METHOD AND DEVICE

Int.Class C12Q 1/6886 Appl.No 15570507 Applicant GENEOSCOPY, LLC Inventor Erica BARNELL

Provided herein are compositions and methods for diagnosis and treatment of colorectal cancer. Methods and kits for detection of colorectal cancer biomarker genes in a stool sample are provided.



### 1. US20180188252 - METHODS FOR DIAGNOSIS AND PROGNOSIS OF EPITHELIAL CANCERS

National Biblio. Data Description Claims Drawings Patent Family Compounds Documents \_\_\_\_\_

PermaLink Machine translation ▼

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[EN]

### Claims

- 1. A method for facilitating the diagnosis of a patient for a cancer of epithelial origin comprising:
- a. obtaining a biological sample from the patient; and
- b. detecting the presence or absence of at least one epithelial cancer biomarker in the biological sample, wherein the presence of at least one epithelial cancer biomarker is indicative of cancer of epithelial origin, and wherein the epithelial cancer biomarker is selected from the group consisting of Cystatin B, Chaperonin 10, and Profilin.
- 2. A method for diagnosing a cancer of epithelial origin in a patient comprising:
- a. measuring at least one epithelial cancer biomarker levels present in a biological sample obtained from the patient, a test sample;
- b. comparing the level of at least one epithelial cancer biomarker in the test sample with the level of epithelial cancer biomarker present in a control

wherein a higher level of at least one epithelial cancer biomarker in the test sample as compared to the level of epithelial cancer biomarker in the control sample is indicative of cancer of epithelial origin, and wherein the epithelial cancer biomarker is selected from the group consisting of Cystatin B, Chaperonin 10, and Profilin.

- 3. The method of claim 1, wherein the cancer of epithelial origin is selected from the group consisting of breast cancer, basal cell carcinoma, adenocarcinoma, gastrointestinal cancer, lip cancer, mouth cancer, esophageal cancer, small bowel cancer, stomach cancer, colon cancer, liver cancer, bladder cancer, pancreas cancer, ovary cancer, cervical cancer, lung cancer, skin cancer, prostate cancer, and renal cell carcinoma.
- 4-6. [canceled]
- 7. The method of claim 1, wherein the biological sample is urine.
- 8. The method of claim 1, wherein the presence or absence of at least one epithelial cancer biomarker or Cystatin B is detected using an antibody-based binding moiety which specifically binds to at least one epithelial cancer biomarker or to Cystatin B.
- 9. The method of claim 2, wherein the level of at least one epithelial cancer biomarker or Cystatin B is measured by measuring the protein level of at least one epithelial cancer biomarker protein or Cystatin B.
- 10. The method of claim 9, wherein the protein level of epithelial cancer biomarker or level of Cystatin B is measured by a method comprising the steps of: a. contacting the test sample, or preparation thereof, with an antibody-based binding moiety which specifically binds the epithelial cancer biomarker or to



4,418 results Offices all Languages all Stemming true Single Family Member false Include NPL false

少等回答口

Download ▼ Machine translation ▼

1020170097956 METHOD FOR SCREENING CANCER BIOMARKERS BY USING CAPILLARY WESTERN BLOT ASSAY


KR - 29.08.2017

Relevance ▼ Perpage: 100 ▼ View: All+Image ▼

Int.Class G01N 33/574 (?) Appl.No 1020160019700 Applicant EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION Inventor SHEEN, YHUN YHONG

The present invention relates to a method for screening cancer biomarkers or cancer metastasis biomarkers using capillary western blot assay. According to the present invention, cancer biomarkers or cancer metastasis biomarkers can be rapidly and precisely screened. Accordingly, the method can be used for developing biomarkers useful for initial diagnosis and clinical stage judgment of cancer. COPYRIGHT KIPO 2017

< 1/45 ▼ >



20150072890 METHODS AND COMPOSITIONS FOR AIDING IN THE DETECTION OF LUNG CANCER

US - 12.03.2015

Int.Class C12Q 1/68 (?) Appl.No 14483503 Applicant William James Inventor William James

A lung cancer biomarker panel comprising an microRNA [miRNA] lung cancer biomarker and at least one additional lung cancer biomarker selected from a tumor protein [TP] lung cancer biomarker and/or a autoantibody [AAB] lung cancer biomarker is provided herein and methods for screening patients for lung cancer. The present lung cancer biomarker panel provides an improvement in sensitivity and diagnostic accuracy for lung cancer as compared to a lung cancer biomarker panel without the miRNA biomarkers.

WO/2020/160108 LIPID BIOMARKERS FOR CANCER SCREENING AND MONITORING

WO - 06.08.2020


Int.Class G01N 33/92 ? Appl.No PCT/US2020/015617 Applicant ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA Inventor CHILTON, Floyd H.

Provided herein are biomarkers for cancer screening and monitoring. In particular, provided herein are lipid biomarkers for cancer diagnosis, risk, and response to treatment.

WO/2017/099414 METHOD FOR DISCOVERY OF MICRORNA BIOMARKER FOR CANCER DIAGNOSIS, AND USE THEREOF

Int.Class 606F 19/18 ? Appl.No PCT/KR2016/013975 Applicant LG ELECTRONICS INC. Inventor LEE, Jaehoon

The present invention relates to a method for discovery of a novel miRNA biomarker for clagnosis, a biomarker for diagnosis of bile duct cancer or pancreatic cancer which has been discovered through the method for discovery of a biomarker, a method for diagnosing cancer, comprising a step in which cancer is diagnosed when f(x) > 0 by substitution of the expression level of the miRNA biomarker, which is detected by the method for discovery of an miRNA biomarker for cancer diagnosis, in a sample into a novel SVM classifier function, a kit for diagnosing bile duct cancer or pancreatic cancer comprising the biomarker for diagnosing bile duct cancer, and a computing device for performing a process of diagnosing cancer when f(x) > 0 as a result of a calculation by substitution of the expression level of an miRNA biomarker which is detected by the method for discovery of an miRNA biomarker for cancer diagnosis, into the novel SVM




WO - 15.06.2017

Close



Filters Charts Timeseries


Offices		Applicants	Inventors	Inventors		IPC code		CPC code		Publication Dates		Kind code	
United States of America	1,372	GENENTECH INC	91 RIEL-MEHAN, MICHAEL	20	G01N	2,905	c12q 1/6886	1,599	2007	91	A	1,788	
PCT	922	NUVARTIS AG	73 ZHANG ZHEN	20	C12Q	2,733	c12q 2600/158	1,019	2008	147	A1	1,381	
China	730	THE JOHNS HOPKINS UNIVERSITY	70 NAKAMURA YUSUKE	18	A61K	982	g01n	821	2009	179	B2	421	
European Patent Office	607	DANA FARBER CANCER INSTITUTE	89 DAIGO YATARO	18	C12N	664	a61p 35/00	809	2010	188	B1	402	
Canada	427	INC SOMALOGIC INC	GOLD, LARRY	18	C07K	574	c12q	520	2011	249	NPL	361	
Republic of Korea	398		JEDDELOH JEFFREY A.	18	A61P	423	c12q 2600/118	472	2012	268	В	182	
Australia	222	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	KORSHUNOVA YULIA	18	G06F	252	g01n 2800/52	484	2013	287	A4	140	
India	139	BAYER PHARMA AG	52 MALONEY REBECCA	18	C40B	185	c12q 2600/106	435	2014	333	T3	41	
Mexico	121	GENOMIC HEALTH INC	40 PENA, CAROL	18	C07H	115	g01n 33/57484	314	2015	316	A2	40	
Japan	114	MYRIAD GENETICS INC	38 FUNG ERIC THOMAS	15	A61B	98	c12q 2600/178	289	2016	337	С	30	
Singapore	97	BAYER HEALTHCARE LLC	BUDIMAN MUHAMMAD A.	14	G16H	70	c12q 2600/156	275	2017	387	A3	13	
Russian Federation	67	MEMORIAL SLOAN KETTERING CANCER CENTER	33 MORGAN, RICHARD	13	G16B	65	c12q 2600/112	287	2018	463	C1	10	
Israel	48		NAKAMURA, YUSUKE	13	C12P	54	a61p	223	2019	510	C2	10	
New Zealand	38		RIEL-MEHAN MICHAEL	13	C12M	48	g01n 33/57423	221	2020	627	A5	7	
Germany	30	OSLO UNIVERSITETSSYKEHUS HF	CHENG, JIE	12	C07D	39	g01n 33/57415	214	2021	201	B8	5	
		THE UNIVERSITY OF SURREY	29										




## Where to find what?

- Help menu
- Search menu
- Tools menu

## Tools



### **WIPO Translate**



[Terms & conditions/User guide]

WIPO Translate NMT is a powerful instant translation tool, designed specifically to translate patent texts (now almost all languages are available using Neural Machine Translation technology). Simply cut and paste text from a patent document into the box below and select from the available language pairs, then click on "Translate" (Note that there is a limit of 2000 characters).

Text to be translated:

IIII的石十 I Iztt,大环的内侧内又表有总压表面,除过空的一响又表有冲夷,上向上针的一响以面有第一下针,下固定杆的一端设置有第二卡杆,该线束KIT车,第一卡杆和第二卡杆卡紧,并将挂环固定在悬挂杆整体内部,而悬挂杆设置在夹环的两侧进而使得布线人员能够在车体两侧进行组装工作,减少布线人员的走动,从而提高工作效率,安装板和凹槽为垂直状态,安装板卡在凹槽表面,线束能够从钩槽处取出,安装板与凹槽平行状态时,安装板卡入凹槽内部,使得钩槽卡在凹槽内,能够将线束固定在挂钩内,便于对线束的取拿与放置。

Language pair: Chinese->English (Neural MT)

Domain:

AUTO-Automotive & Road Vehicle Engineering

Translate

This automatic translation is provided for information only, it may contain discrepancies or mistakes and does not have any juridical value

- Please hover your mouse over parallel segments of text
- Click to view other proposals
- · Select words or phrases on the left to access other translation proposals

本实用新型涉及机械技术领域,尤其为一种线束 kit 车,包括车体, 安装在车体底部的脚轮以及安装在车体外表面的若干个挂杆, 夹环的两侧均安装有悬挂装置, 限位垫的一端安装有弹簧, 上固定杆的一端设置有第一卡杆, 下固定杆的一端设置有第二卡杆, 该线束 kit 车, 第一卡杆和第二卡杆卡紧, 并将挂环固定在悬挂杆整体内部,而悬挂杆设置在夹环的两侧进而使得布线人员能够在车体两侧进行组装工作,减少布线, 员的走动, 从而提高工作效率, 安装板和凹槽为垂直状态, 安装板卡在凹槽表面,线束能够从钩槽处取出, 安装板与凹槽平行状态时, 安装板卡入凹槽内部,使得钩槽卡在凹槽内,能够将线束固定在挂钩内,便于对线束的取拿与放置。

the invention relates to the technical field of machinery, in particular to a wire harness kit vehicle which comprises a vehicle body, a foot wheel installed at the bottom of the car body, and a plurality of hanging rods arranged on the outer surface of the car body; the two sides of the clamping ring are respectively provided with a suspension device, a spring is arranged at one end of the limiting pad, a first clamping rod is arranged at one end of the upper fixing rod, and a second clamping rod is arranged at one end of the lower fixing rod, the wire harness kit vehicle, the first clamping rod and the second clamping rod are clamped, and the hanging ring is fixed in the whole suspension rod, and the suspension rods are arranged on the two sides of the clamp ring, so that the wiring personnel can assemble and work on the two sides of the vehicle body, the walking of wiring personnel is reduced, so that the working efficiency is improved, the mounting plate and the groove are in a vertical state, and the mounting plate is clamped on the surface of the groove, the wire harness can be taken out from the hook groove, and when the mounting plate is parallel to the groove, the mounting plate is clamped into the groove, so that the hook groove is clamped in the groove, the wire harness can be fixed in the hook, and the wire harness can be taken and placed conveniently.

Edit translation

本 实用 新型 涉及 机械 技术 领域, 尤其 为 一 种 线 束 kit 车,包括 车体,安装在车体底部的脚轮以及安装在车体外表面的若干个 挂杆,夹环的两侧均安装有悬挂装置。限位垫的一端安装有 弹簧,上固定杆的一端设置有第一卡杆,下固定杆的一端设 置有第二卡杆,该线束kit车,第一卡杆和第二卡杆卡紧,并 将挂环固定在悬挂杆整体内部,而悬挂杆设置在夹环的两侧 进而 使 得 布 线 人员 能够 在 车体 两侧 进行 组装 工作, 减少 布 线 人 员的走动,从而提高工作效率,安装板和凹槽为垂直状态,安 装板卡在凹槽表面,线束能够从钩槽处取出,安装板与凹槽 平行状态时,安装板卡入凹槽内部,使得钩槽卡在凹槽内,能 够将线束固定在挂钩内,便于对线束的取拿与放置。

are in a vertical state, and the mounting plate is clamped on the surface of the groove, the wire harness can be taken out from the

■Choose among proposals, or edit the text

the walking of wiring personnel is reduced, so A that the working efficiency is improved, the mounting plate and the groove are in a vertical

the invention relates to the technical field of machinery, in particular to a wire harness kit vehicle which comprises a vehicle body, a foot wheel installed at the bottom of the car body, and a plurality of hanging rods arranged on the outer surface of the car body; the two

suspension device, a spring is arranged at one end of the limiting

pad, a first clamping rod is arranged at one end of the upper fixing rod, and a second clamping rod is arranged at one end of the lower

fixing rod, the wire harness kit vehicle, the first clamping rod and

fixed in the whole suspension rod, and the suspension rods are

personnel can assemble and work on the two sides of the vehicle

working efficiency is improved, the mounting plate and the groove

the second clamping rod are clamped, and the hanging ring is

arranged on the two sides of the clamp ring, so that the wiring

body, the walking of wiring personnel is reduced, so that the

sides of the clamping ring are respectively provided with a

Ok

Edit translation

#### ated links

- WIPO Translate: Cutting-Edge Translation Tool For Patent Docum
- . Interested in your own version of WIPO Translate? Find out more

the walking of wiring personnel is reduced , so that the working efficiency is improved, the mounting plate and the groove are in a vertical state, and the mounting plate is clamped on the surface of the groove

the walking of wiring personnel is reduced, and therefore the working efficiency is improved; the mounting plate and the groove are in a vertical state, and the mounting plate is clamped on the surface of the groove

the walking of wiring personnel is reduced, so that the working efficiency is improved, the mounting plate and the groove are in the vertical state, and the mounting plate is clamped on the surface of the groove


the walking of wiring personnel is reduced, the working efficiency is improved, the mounting plate and the groove are in a vertical state, and the mounting plate is clamped on the surface of the groove

the walking of wiring personnel is reduced, and therefore the working efficiency is improved; the mounting plate and the groove are in the vertical state, and the mounting plate is clamped on the surface of the groove

and therefore the working efficiency is improved; the mounting plate and the groove are in a vertical state, and the mounting plate is clamped on the surface of the groove

and the walking of wiring personnel is reduced, so that the working efficiency is improved, the mounting plate and the groove are in a vertical state, and the mounting plate is clamped on the surface of the groove

### **WIPO Pearl**




Reliability 3 / 4

0.00

FR > lave-vaisselle

# IPC Green Inventory



### **IPC GREEN INVENTORY**

The "IPC Green Inventory", developed by the IPC Committee of Experts, facilitates searches for patent information relating to Environmentally Sound Technologies (ESTs), as listed by the United Nations Framework Convention on Climate Change (UNFCCC). ESTs are currently scattered widely across the IPC in numerous technical fields. The Inventory attempts to collect them in one place.

For more information about how to use the IPC Green Inventory please click here.

The Inventory does not purport to be fully exhaustive in its coverage

TOPIC	IPC	PATENTSCOPE
▶ ALTERNATIVE ENERGY PRODUCTION		
▶ TRANSPORTATION		
► ENERGY CONSERVATION		
▶ WASTE MANAGEMENT		
▶ AGRICULTURE / FORESTRY		
▶ ADMINISTRATIVE, REGULATORY OR DESIGN ASPECTS		
▶ NUCLEAR POWER GENERATION		

### **IPC GREEN INVENTORY**

The "IPC Green Inventory", developed by the IPC Committee of Experts, facilitates searches for patent information relating to Environmentally Sound Technologies (ESTs), as listed by the United Nations Framework Convention on Climate Change (UNFCCC). ESTs are currently scattered widely across the IPC in numerous technical fields. The Inventory attempts to collect them in one place.

For more information about how to use the IPC Green Inventory please click here.


The Inventory does not purport to be fully exhaustive in its coverage

**▶ NUCLEAR POWER GENERATION** 

TOPIC	IPC	PATENTSCOPE	
► ALTERNATIVE ENERGY PRODUCTION			
▼ TRANSPORTATION			
▶ VEHICLES IN GENERAL			
▶ VEHICLES OTHER THAN RAIL VEHICLES			
▶ RAIL VEHICLES	<u>B61</u>	<u>B61</u>	
▶ MARINE VESSEL PROPULSION			
COSMONAUTIC VEHICLES USING SOLAR ENERGY	<u>B64G 1/44</u>	<u>B64G 1/44</u>	
► ENERGY CONSERVATION			
▶ WASTE MANAGEMENT			
▶ AGRICULTURE / FORESTRY			
▶ ADMINISTRATIVE, REGULATORY OR DESIGN ASPECTS			

### How to contact us?

- Feedback
- Contact us in help menu
- patentscope@wipo.int



# Future/past webinars:

#### **PATENTSCOPE** Webinars

WIPO offers free online seminars (webinars) to deliver information, training and updates on the PATENTSCOPE Search System. If you or your organization are interested in a webinar on a specific topic, please contact us.

wipo.int/patentscope/en/webinar

### Register for upcoming webinars

All PATENTSCOPE webinars

#### PATENTSCOPE for Beginners

June 7, 2022 (English) 17:30 - 18:15 Geneva time

Online registration

#### PATENTSCOPE for Beginners

June 9, 2022 (English) 08:30 - 09:15 Geneva time

Online registration

#### Summer School – PATENTSCOPE - Session 1

July 6, 2022 (English) 16:00 - 17:30 Geneva time

Online registration

#### Summer School – PATENTSCOPE - Session 2

July 20, 2022 (English) 16:00 - 17:30 Geneva time

Online registration



